share_log

PRE 14A: Preliminary proxy statements relating to merger or acquisition

PRE 14A: Preliminary proxy statements relating to merger or acquisition

PRE 14A：并购重组委托声明
美股SEC公告 ·  08/31 05:13

Moomoo AI 已提取核心信息

ZyVersa Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the scheduling of its 2024 Annual Meeting of Stockholders to be held virtually on October 29, 2024. The meeting will invite stockholders to elect one Class II director nominee, Dr. Min Chul Park, for a three-year term, ratify the selection of Marcum LLP as the independent registered public accounting firm for the year ending December 31, 2024, approve an amendment to increase the number of shares reserved under the 2022 Omnibus Equity Incentive Plan, and approve the issuance of shares upon the exercise of certain warrants in accordance with Nasdaq Listing Rule 5635(d). The record date for the Annual Meeting is set for September 4, 2024, with only stockholders of record at the close of business on that date or their proxies eligible to vote. The company emphasizes the importance of stockholder participation and encourages the submission of proxies prior to the meeting.
ZyVersa Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the scheduling of its 2024 Annual Meeting of Stockholders to be held virtually on October 29, 2024. The meeting will invite stockholders to elect one Class II director nominee, Dr. Min Chul Park, for a three-year term, ratify the selection of Marcum LLP as the independent registered public accounting firm for the year ending December 31, 2024, approve an amendment to increase the number of shares reserved under the 2022 Omnibus Equity Incentive Plan, and approve the issuance of shares upon the exercise of certain warrants in accordance with Nasdaq Listing Rule 5635(d). The record date for the Annual Meeting is set for September 4, 2024, with only stockholders of record at the close of business on that date or their proxies eligible to vote. The company emphasizes the importance of stockholder participation and encourages the submission of proxies prior to the meeting.
ZyVersa Therapeutics, Inc.，一家临床阶段的生物制药公司，宣布将于2024年10月29日以虚拟形式举行其2024年股东大会。本次会议将邀请股东选举一名二等级董事候选人Dr. Min Chul Park，任期三年，批准Marcum LLP为截至2024年12月31日的独立注册会计师事务所的选择，批准修改2022年全权股票激励计划下保留股票数量的修正案，并根据纳斯达克上市规则5635(d)批准根据特定认股权行使发行股票。年度股东大会的登记日期定于2024年9月4日，只有在该日期营业结束时登记的股东或其代理人有资格进行投票。公司强调股东参与的重要性，并鼓励在会议之前提交委托表。
ZyVersa Therapeutics, Inc.，一家临床阶段的生物制药公司，宣布将于2024年10月29日以虚拟形式举行其2024年股东大会。本次会议将邀请股东选举一名二等级董事候选人Dr. Min Chul Park，任期三年，批准Marcum LLP为截至2024年12月31日的独立注册会计师事务所的选择，批准修改2022年全权股票激励计划下保留股票数量的修正案，并根据纳斯达克上市规则5635(d)批准根据特定认股权行使发行股票。年度股东大会的登记日期定于2024年9月4日，只有在该日期营业结束时登记的股东或其代理人有资格进行投票。公司强调股东参与的重要性，并鼓励在会议之前提交委托表。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间